On February 22, 2019, our firm filed a class action lawsuit on behalf of Amarin Corporation (NASDAQ: AMRN) investors who purchased shares between September 24, 2018 and November 9, 2018. The lawsuit seeks to recover damages for investors under the federal securities laws.

If you are an Amarin investor, we may be able to help you recover your losses.

Recover Your Amarin Losses. (NASDAQ: AMRN)

You may have a legal claim.  Speak to an attorney about your rights.

  • This field is for validation purposes and should be left unchanged.

800-254-9493

Amarin Corp. Stock Plunges 27% Following Publication of Vascepa Study

Last year, Amarin Corporation previewed to the public the results of a recently completed cardiovascular study relating to the drug Vascepa. The study would reportedly show a 25% relative risk reduction in certain cardiovascular events patients taking Vascepa, a drug developed by Amarin.  Amarin’s stock saw a 300% increase in value, from $2.99 to $12.40.

On November 10, 2018, scientists involved in the study presented more information about the study and its results. It has been reported that the additional information provided suggests the placebo used in the study, mineral oil, may have caused cardiovascular problems in patients taking it. Some believe that this meant that the study did not demonstrate that Vascepa lowered the risk of cardiovascular problems as previously reported. After this news was reported, Amarin stock decreased in value by 27% from $21.05 to $15.38 in about two days.

Gibbs Law Group's Financial Fraud Experience

Gibbs Law Group’s financial fraud and securities lawyers have more than two decades of experience prosecuting fraud. Our attorneys have successfully litigated against some of the largest companies in the United States, and we have recovered more than a billion dollars on our clients’ behalf.

We have fought some of the most complex cases brought under federal and state laws nationwide, and our attorneys have been recognized with numerous awards and honors for their accomplishments, including Top 100 Super Lawyers in Northern California, Top Plaintiff Lawyers in California, The Best Lawyers in America, and rated AV Preeminent (among the highest class of attorneys for professional ethics and legal skills).

Noteworthy Financial Fraud Cases

American Express Financial Advisors Securities Litigation $100 million cash settlement for clients alleging American Express steered them into under-performing “shelf space funds” to reap kickbacks
Chase Bank “Check Loan” Litigation $100 million settlement for consumers alleging Chase offered long-term fixed-rate loans, only to later more-than-double required payments
Peregrine Financial Group Customer Litigation Settlements worth $75 million for futures and commodities investors who lost millions in the collapse of Peregrine Financial Group, Inc.
NantHealth Court-appointed Co-Lead Counsel in a securities class action alleging the company’s founder violated federal securities law and artificially inflated stock prices

Our Securities Attorneys

Eric Gibbs

Eric has served in leadership positions in a number of high profile, complex financial lawsuits. He has been recognized as a Daily Journal, among the Top 100 Super Lawyers in Northern California, and a Law360 MVP for Consumer Protection.

David Stein

David’s advocacy has generated major recoveries for consumers impacted by financial fraud. He was named to the Top 40 Under 40 by Daily Journal and a “Rising Star in Class Actions” by Law360.

Michael Schrag

Michael has over 20 years of experience representing individuals in complex cases involving banking credit card and other financial frauds.

Amanda Karl

Amanda represents employees, consumers and investors in complex class action lawsuits throughout the country. She previously served as a law clerk to the Honorable Richard A. Paez, United States Court of Appeals for the Ninth Circuit, and to the Honorable Claudia Wilken, Northern District of California.

AMRN stock losses?

Speak to a securities attorney to recover your money. Free, confidential consultations.

  • This field is for validation purposes and should be left unchanged.

800-254-9493